请输入您要查询的百科知识：

　

词条 Benitec Biopharma
释义

  1. Partnerships and Collaborations

  2. Research and development

  3. References

  4. External links

{{Multiple issues|{{Orphan|date=February 2017}}{{COI|date=June 2014}}
}}{{Use Australian English|date=July 2016}}{{Use dmy dates|date=July 2016}}{{Infobox company
| name = Benitec Biopharma Ltd
| logo =
| type = Biotechnology
| traded_as = {{ASX|BLT}}
| foundation = 1997
| location = Sydney
| key_people = Peter Francis {{small|(Chairman)}}
Greg West {{small|(CEO)}}
Bryan Dulhunty {{small|(CFO)}}
Michael Graham {{small|(Founding Scientist & Head of Discovery)}}
| revenue = $1,464,1782 (2013)[1]
| net_income = ($4,801,752) (2013)[1]
| assets = $1,750,710 (2013)[1]
| equity = $640,340 (2013)[1]
| num_employees = 7 (2013)[1]
| industry = RNA interference
| products = Gene silencing, Gene expression, RNA interference (ddRNAi)
| homepage = www.benitec.com
}}Benitec Biopharma Ltd {{ASX|BLT}} is an Australian biotechnology company founded in 1997.[2] It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.[3]

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.[4]

{{TOC limit|limit=3}}

The proof is in the pudding for Benitec's stocks offerings of both shares and warrants as it relates to their R&D and finalized product. Benitec's stock was at twenty two dollars a share in late 2014 and as of late January 2019, the stock has plummeted to one dollar forty six cents, questioning the actual scientific productivity and licencing for the entire spread of Bentitec's goals not just limited to scientific breakthroughs but to actually licence, distribute and partner, alleged scientific papers and the intellectual property value of a number of their scientific claims as marketable products.

Partnerships and Collaborations

Benitec Biopharma and its subsidiary Tacere Therapeutics has partnerships with:[1][3][5]

  • For laboratory reagents: Promega, Chemicon (Millipore Corporation), Integrated DNA Technologies, Genscript, Ambion Inc (Applied Biosystems), Origene Technologies Inc, Sigma Aldrich
  • For transgenic animals: Artemis Pharmaceutical GmbH, GenOway
  • For commercial research use: Merck & Co, Pfizer
  • Licensing agreements: Calimmune (US), Carnegie Institution for Science (University of Massachusetts, US), Children's Cancer Institute Australia for Medical Research (CCIA) (University of New South Wales, Australia), Biomics Biotechnologies (China), Genable Technologies (Ireland), Stanford University (US), Royal Holloway (University of London, UK), Revivicor (US), Regen BioPharma (a subsidiary of Bio-Matrix, US), and UniQure BV (the Netherlands).

Research and development

Benitec Biopharma and its partners and licensees are researching ddRNAi in the following fields:

  • Hepatitis C (under development by subsidiary Tacere Therapeutics; Phase I/II trial; NCT01899092)[1][6]
  • Hepatitis B (under development with partner Biomics Biotechnologies)[1][7])
  • HIV (under development by Calimmune; Phase I/II trial; NCT01899092)[1][8]
  • Neuropathic pain[9][10]
  • Drug-resistant non-small cell lung cancer (under development by Children's Cancer Institute Australia)[11]
  • Oculopharyngeal muscular dystrophy (OPMD)[1][9][12]
  • Autosomal dominant retinitis pigmentosa (under development by partner Genable Technologies)[10][13]
  • Wet age-related macular degeneration (under development with subsidiary Tacere Therapeutics)[1]
  • Huntington's disease (under development by partner uniQure).[1][14]

References

1. ^1 2 3 4 5 6 7 8 9 10 11 {{cite web |url=http://www.benitec.com/documents/BLTAnnualreport2013.pdf |title=Benitec Biopharma Annual Report 2013 |accessdate=16 January 2014 |publisher=Benitec }}{{dead link|date=July 2017 |bot=InternetArchiveBot |fix-attempted=yes }}
2. ^{{cite web |url=http://www.asx.com.au/asx/research/companyInfo.do?by=asxCode&asxCode=BLT |title=Australian Securities Exchange|accessdate=11 April 2012 |publisher=ASX}}
3. ^1 {{cite web |url=http://www.globalcompanyintelligence.com/Report.aspx?ID=Benitec-Biopharma-Limited-BLT-Financial-and-Strategic-SWOT-Analysis-Review&ReportType=Company_Report&TitleId=26&Title=Pharmaceuticals_and_Healthcare |archive-url=https://archive.is/20130124015333/http://www.globalcompanyintelligence.com/Report.aspx?ID=Benitec-Biopharma-Limited-BLT-Financial-and-Strategic-SWOT-Analysis-Review&ReportType=Company_Report&TitleId=26&Title=Pharmaceuticals_and_Healthcare |dead-url=yes |archive-date=24 January 2013 |title=GlobalData Financial and Strategic SWOT Analysis Review |accessdate=11 April 2012 |publisher=GlobalData }}
4. ^{{cite web|url= http://www.csiro.au/Outcomes/Food-and-Agriculture/Licensing-RNAi-gene-technology.aspx|title= Licensing RNAi gene technology. CSIRO. 14 Oct 2011|accessdate= 12 April 2012|publisher= CSIRO|deadurl= yes|archiveurl= https://web.archive.org/web/20120518173449/http://www.csiro.au/Outcomes/Food-and-Agriculture/Licensing-RNAi-gene-technology.aspx|archivedate= 18 May 2012|df= dmy-all}}
5. ^{{cite web|url= http://www.lifescientist.com.au/article/137334/csiro_benitec_strengthen_rnai_patent_positions/|title= Australian Life Scientist. CSIRO, Benitec strengthen RNAi patent positions. 24 October 2005|accessdate= 12 April 2012|publisher= Australian Life Scientist|deadurl= yes|archiveurl= https://web.archive.org/web/20091015075019/http://www.lifescientist.com.au/article/137334/csiro_benitec_strengthen_rnai_patent_positions|archivedate= 15 October 2009|df= dmy-all}}
6. ^{{cite web |url=http://clinicaltrials.gov/ct2/show/NCT01899092|title=Clinical Trial NCT01899092|accessdate=16 January 2014 |publisher=US National Institute of Health}}
7. ^{{cite web |url=http://www.biomics.cn/en/Pipeline.html|title=Biomics Biotechnologies – Pipeline|accessdate=21 January 2014 |publisher=Biomics Biotechnologies}}
8. ^{{cite web |url=http://clinicaltrials.gov/ct2/show/NCT01734850|title=Clinical Trial NCT01734850|accessdate=16 January 2014 |publisher=US National Institute of Health}}
9. ^1 {{cite web |url= http://www.benitec.com/documents/Bioshares434rbpBLT.pdf |title= Bioshares Edition 434. 25 November 2011|accessdate=21 January 2014 |publisher=Bioshares}}
10. ^1 {{cite web |url=http://www.benitec.com/documents/12%2010%2017%20BLT%20Ann%20Report%202012.pdf |title=Benitec Biopharma Annual Report 2012|accessdate=16 January 2014 |publisher=Benitec}}
11. ^{{cite web |url= http://newsroom.unsw.edu.au/news/health/cancer-collaboration|title= Cancer Collaboration. 10 May 2011|accessdate=21 January 2014 |publisher=UNSW Australia}}
12. ^{{cite web |url=http://www.benitec.com/documents/BenitecAnnualReport2011_Final.pdf |title=Benitec Biopharma Annual Report 2011|accessdate=16 January 2014 |publisher=Benitec}}
13. ^{{cite web |url= http://www.blindness.org/index.php?view=article&id=2978%3Agenable-receives-68-million-investment-to-develop-gene-therapy-for-dominant-rp&option=com_content&Itemid=121|title= Genable Receives $6.8 Million Investment to Develop Gene Therapy for Dominant RP|accessdate=16 January 2014 |publisher=Foundation Fighting Blindness}}
14. ^{{cite web |url= http://www.prnewswire.com/news-releases/uniqure-licenses-rna-interference-technology-to-advance-huntingtons-disease-program-182131601.html|title= uniQure licenses RNA interference technology to advance Huntington's disease program |accessdate=21 January 2014 |publisher=PR Newswire}}

External links

  • Benitec Biopharma website

11 : Biotechnology companies of Australia|Stem cells|Biopharmaceutical companies|Genetic engineering|Companies based in Sydney|Multinational companies headquartered in Australia|Biotechnology companies established in 1997|Companies listed on the Australian Securities Exchange|Australian brands|Pharmaceutical companies established in 1997|1997 establishments in Australia
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/14 13:38:32